Literature DB >> 24606313

Targeted inhibition of KCa3.1 attenuates TGF-β-induced reactive astrogliosis through the Smad2/3 signaling pathway.

Zhihua Yu1,2, Panpan Yu2, Hongzhuan Chen1, Herbert M Geller2.   

Abstract

Reactive astrogliosis, characterized by cellular hypertrophy and various alterations in gene expression and proliferative phenotypes, is considered to contribute to brain injuries and diseases as diverse as trauma, neurodegeneration, and ischemia. KCa3.1 (intermediate-conductance calcium-activated potassium channel), a potassium channel protein, has been reported to be up-regulated in reactive astrocytes after spinal cord injury in vivo. However, little is known regarding the exact role of KCa3.1 in reactive astrogliosis. To elucidate the role of KCa3.1 in regulating reactive astrogliosis, we investigated the effects of either blocking or knockout of KCa3.1 channels on the production of astrogliosis and astrocytic proliferation in response to transforming growth factor (TGF)-β in primary cultures of mouse astrocytes. We found that TGF-β increased KCa3.1 protein expression in astrocytes, with a concomitant marked increase in the expression of reactive astrogliosis, including glial fibrillary acidic protein and chondroitin sulfate proteoglycans. These changes were significantly attenuated by the KCa3.1 inhibitor 1-((2-chlorophenyl) (diphenyl)methyl)-1H-pyrazole (TRAM-34). Similarly, the increase in glial fibrillary acidic protein and chondroitin sulfate proteoglycans in response to TGF-β was attenuated in KCa3.1(-/-) astrocytes. TRAM-34 also suppressed astrocytic proliferation. In addition, the TGF-β-induced phosphorylation of Smad2 and Smad3 proteins was reduced with either inhibition of KCa3.1 with TRAM-34 or in KCa3.1(-/-) astrocytes. These findings highlight a novel role for the KCa3.1 channel in reactive astrogliosis phenotypic modulation and provide a potential target for therapeutic intervention for brain injuries. Reactive astrogliosis is characterized by the expression of glial fibrillary acidic protein and chondroitin sulfate proteoglycans. We demonstrate that either pharmacological blockade or knockout of KCa3.1 channels reduces reactive gliosis in cultured astrocytes caused by TGF-β, and also reduces TGF-β-induced phosphorylation of Smad2/3. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  GFAP; astrocyte; chondroitin sulfate proteoglycans; culture; mouse

Mesh:

Substances:

Year:  2014        PMID: 24606313      PMCID: PMC4065629          DOI: 10.1111/jnc.12710

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  40 in total

1.  The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke.

Authors:  Yi-Je Chen; Girija Raman; Silke Bodendiek; Martha E O'Donnell; Heike Wulff
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-13       Impact factor: 6.200

Review 2.  The TGFbeta superfamily signaling pathway.

Authors:  Alexander Weiss; Liliana Attisano
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012-10-05       Impact factor: 5.814

Review 3.  Glial cell extracellular matrix: boundaries for axon growth in development and regeneration.

Authors:  M T Fitch; J Silver
Journal:  Cell Tissue Res       Date:  1997-11       Impact factor: 5.249

4.  Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence.

Authors:  A Bignami; L F Eng; D Dahl; C T Uyeda
Journal:  Brain Res       Date:  1972-08-25       Impact factor: 3.252

5.  Up-regulation of KCa3.1 promotes human airway smooth muscle cell phenotypic modulation.

Authors:  Z-H Yu; Y-X Wang; Y Song; H-Z Lu; L-N Hou; Y-Y Cui; H-Z Chen
Journal:  Pharmacol Res       Date:  2013-09-18       Impact factor: 7.658

6.  Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells.

Authors:  E Schönherr; H T Järveläinen; L J Sandell; T N Wight
Journal:  J Biol Chem       Date:  1991-09-15       Impact factor: 5.157

7.  Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat.

Authors:  A Logan; M Berry; A M Gonzalez; S A Frautschy; M B Sporn; A Baird
Journal:  Eur J Neurosci       Date:  1994-03-01       Impact factor: 3.386

8.  Blockade of KCa3.1 ameliorates renal fibrosis through the TGF-β1/Smad pathway in diabetic mice.

Authors:  Chunling Huang; Sylvie Shen; Qing Ma; Jason Chen; Anthony Gill; Carol A Pollock; Xin-Ming Chen
Journal:  Diabetes       Date:  2013-05-08       Impact factor: 9.461

9.  The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosis.

Authors:  Katy M Roach; Katy Morgan Roach; Stephen Mark Duffy; William Coward; Carol Feghali-Bostwick; Heike Wulff; Peter Bradding
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 10.  How do astrocytes shape synaptic transmission? Insights from electrophysiology.

Authors:  Glenn Dallérac; Oana Chever; Nathalie Rouach
Journal:  Front Cell Neurosci       Date:  2013-10-01       Impact factor: 5.505

View more
  24 in total

1.  Astrocytes from the brain microenvironment alter migration and morphology of metastatic breast cancer cells.

Authors:  Marina A Shumakovich; Caitlin P Mencio; Jonathan S Siglin; Rebecca A Moriarty; Herbert M Geller; Kimberly M Stroka
Journal:  FASEB J       Date:  2017-08-09       Impact factor: 5.191

2.  Myelin phagocytosis by astrocytes after myelin damage promotes lesion pathology.

Authors:  Gerald Ponath; Sriram Ramanan; Mayyan Mubarak; William Housley; Seunghoon Lee; F Rezan Sahinkaya; Alexander Vortmeyer; Cedric S Raine; David Pitt
Journal:  Brain       Date:  2016-12-21       Impact factor: 13.501

3.  Astrocytes from the brain microenvironment alter migration and morphology of metastatic breast cancer cells.

Authors:  Marina A Shumakovich; Caitlin P Mencio; Jonathan S Siglin; Rebecca A Moriarty; Herbert M Geller; Kimberly M Stroka
Journal:  FASEB J       Date:  2017-11       Impact factor: 5.191

Review 4.  Reactive astrocytes and therapeutic potential in focal ischemic stroke.

Authors:  Gourav Roy Choudhury; Shinghua Ding
Journal:  Neurobiol Dis       Date:  2015-05-14       Impact factor: 5.996

5.  Neuroprotective Effects of Direct Intrathecal Administration of Granulocyte Colony-Stimulating Factor in Rats with Spinal Cord Injury.

Authors:  Wu-Fu Chen; Chun-Hong Chen; Nan-Fu Chen; Chun-Sung Sung; Zhi-Hong Wen
Journal:  CNS Neurosci Ther       Date:  2015-07-20       Impact factor: 5.243

6.  Overexpressed ski efficiently promotes neurorestoration, increases neuronal regeneration, and reduces astrogliosis after traumatic brain injury.

Authors:  Yu Zhai; Shi-Yang Ye; Qiu-Shi Wang; Ren-Ping Xiong; Sheng-Yu Fu; Hao Du; Ya-Wei Xu; Yan Peng; Zhi-Zhong Huang; Nan Yang; Yan Zhao; Ya-Lei Ning; Ping Li; Yuan-Guo Zhou
Journal:  Gene Ther       Date:  2022-02-08       Impact factor: 5.250

7.  KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.

Authors:  Mengni Yi; Panpan Yu; Qin Lu; Herbert M Geller; Zhihua Yu; Hongzhuan Chen
Journal:  Mol Cell Neurosci       Date:  2016-08-24       Impact factor: 4.314

8.  Tocotrienol alleviates inflammation and oxidative stress in a rat model of spinal cord injury via suppression of transforming growth factor-β.

Authors:  Chuanhui Xun; Mardan Mamat; Hailong Guo; Pulat Mamati; Jun Sheng; Jian Zhang; Tao Xu; Weidong Liang; Rui Cao; Weibin Sheng
Journal:  Exp Ther Med       Date:  2017-05-23       Impact factor: 2.447

9.  Midazolam's Effects on Delayed-Rectifier K+ Current and Intermediate-Conductance Ca2+-Activated K+ Channel in Jurkat T-lymphocytes.

Authors:  Ning-Ping Foo; Yu-Fan Liu; Ping-Ching Wu; Chung-Hsi Hsing; Bu-Miin Huang; Edmund-Cheung So
Journal:  Int J Mol Sci       Date:  2021-07-04       Impact factor: 5.923

10.  TRPV1 sustains microglial metabolic reprogramming in Alzheimer's disease.

Authors:  Jia Lu; Wei Zhou; Fangfang Dou; Chenfei Wang; Zhihua Yu
Journal:  EMBO Rep       Date:  2021-05-17       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.